Abstract

The manufacturer-supported STEP 1 and STEP 3 trials examined use of semaglutide as a weight-loss drug in obese nondiabetic patients (NEJM JW Gen Med

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call